−0.4103USD
−17.19 MUSD
56.13 M
About Brainstorm Cell Therapeutics Inc.
Sector
Industry
CEO
Chaim Lebovits
Website
Headquarters
New York
Employees (FY)
29
Founded
2000
ISIN
US10501E2019
FIGI
BBG000FR6HQ1
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BCLI is 0.5143 USD — it has decreased by 4.90% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Brainstorm Cell Therapeutics Inc. stocks are traded under the ticker BCLI.
Brainstorm Cell Therapeutics Inc. is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
BCLI stock is 30.76% volatile and has beta coefficient of 3.64. Check out the list of the most volatile stocks — is Brainstorm Cell Therapeutics Inc. there?
BCLI earnings for the last quarter are −0.03 USD whereas the estimation was −0.15 USD which accounts for 80.00% surprise. Estimated earnings for the next quarter are −0.11 USD. See more details about Brainstorm Cell Therapeutics Inc. earnings.
Brainstorm Cell Therapeutics Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 750.00 K USD. In the next quarter revenue is expected to reach 750.00 K USD.
Yes, you can track Brainstorm Cell Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
BCLI stock has fallen by 12.83% compared to the previous week, the month change is a 51.94% rise, over the last year Brainstorm Cell Therapeutics Inc. has showed a 80.07% decrease.
BCLI net income for the last quarter is −5.58 M USD, while the quarter before that showed −1.23 M USD of net income which accounts for −354.98% change. Track more Brainstorm Cell Therapeutics Inc. financial stats to get the full picture.
Today Brainstorm Cell Therapeutics Inc. has the market capitalization of 36.96 M, it has increased by 41.66% over the last week.
No, BCLI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BCLI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Brainstorm Cell Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 29.00 employees. See our rating of the largest employees — is Brainstorm Cell Therapeutics Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Brainstorm Cell Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Brainstorm Cell Therapeutics Inc. stock shows the sell signal. See more of Brainstorm Cell Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.